(Q44226295)

English

Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699). (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

5

object named as

Jos H Beijnen

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

author name string

Rolf W Sparidans

2

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Anita van Esch

3

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Els Wagenaar

4

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Alfred H Schinkel

6

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

publication date

25 June 2014

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Pharmaceutical Research

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

37-46

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

P-glycoprotein limits oral availability, brain penetration, and toxicity of an anionic drug, the antibiotic salinomycin

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amin

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

Hepatic clearance of reactive glucuronide metabolites of diclofenac in the mouse is dependent on multiple ATP-binding cassette efflux transporters

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

PARP inhibition: PARP1 and beyond

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets.

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

Role of PARP inhibitors in cancer biology and therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

Targeting the BRCA1/2 tumor suppressors

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

Liquid chromatography-tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma.

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

Targeting multidrug resistance in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

ATP binding cassette transporters and drug resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

Mrp4 confers resistance to topotecan and protects the brain from chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

Breast cancer metastasis to the central nervous system

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

1 reference

https://api.crossref.org/works/10.1007%2FS11095-014-1442-Z

21 January 2018

P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration

1 reference

https://pubmed.ncbi.nlm.nih.gov/24962512

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Brain metastases from ovarian carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24962512

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11095-014-1442-Z

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44226295&oldid=2108734023"